SHAREHOLDERS' EQUITY - Narrative (Details)				3 Months Ended		9 Months Ended		46 Months Ended
	Nov. 17, 2022 USD ($) $ / shares shares	Feb. 04, 2020 USD ($) sales_agent	Jul. 18, 2011	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Aug. 31, 2022 USD ($)	Aug. 02, 2022 USD ($)	Aug. 01, 2022 USD ($)	Jul. 28, 2021 USD ($)	May 26, 2021 USD ($)	Mar. 04, 2019 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Right to grant period			10 years
Stock repurchase program, authorized amount									$ 20,000,000			$ 20,000,000
Public Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Number of shares sold (in shares) | shares	2,534,436
Par value, common stock (in usd per share) | $ / shares	$ 18.15
Gross proceeds received	$ 46,000,000
Net proceeds received	$ 44,100,000
Equity ATM Program
Subsidiary or Equity Method Investee [Line Items]
Number of shares sold (in shares) | shares				3,264,878	616,156	6,909,446	2,834,734	15,087,106
Gross proceeds received				$ 58,324,000	$ 16,000,000	$ 131,990,000	$ 74,463,000	$ 315,500,000
Net proceeds received				$ 57,449,000	$ 15,760,000	$ 130,010,000	$ 73,347,000	$ 310,300,000
Maximum consideration threshold		$ 100,000,000								$ 650,000,000	$ 250,000,000		$ 250,000,000	$ 50,000,000
Number of additional sales agents | sales_agent		2
Gross sales commission percentage													1.50%	2.00%
Weighted average price per share (in usd per share) | $ / shares				$ 17.86	$ 25.97	$ 19.10	$ 26.27	$ 20.91
Available under the Equity ATM Program				$ 334,500,000		$ 334,500,000		$ 334,500,000
2010 Plan | Restricted Stock
Subsidiary or Equity Method Investee [Line Items]
Right to grant period			10 years